尔康制药(300267) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥383,793,068.50, a decrease of 12.99% compared to the same period last year[8] - Net profit attributable to shareholders was ¥53,028,821.97, representing a significant increase of 145.07% year-over-year[8] - The net profit after deducting non-recurring gains and losses was ¥42,468,087.51, up 167.28% from the previous year[8] - Basic and diluted earnings per share rose to ¥0.0257, reflecting a growth of 144.76% compared to the previous year[8] - The company's financial expenses increased by 101.29% to 1.29 million yuan due to a decrease in exchange gains[20] - Investment income rose by 120.64% to 5.45 million yuan, primarily due to increased returns from financial products[20] - The sales revenue from pharmaceutical excipients was 185.60 million yuan, down 38.50% year-on-year[23] - The sales revenue from raw materials increased by 10.60% to 105.56 million yuan[24] - The sales revenue from finished drugs surged by 163.00% to 61.50 million yuan[24] - Total operating revenue for Q1 2021 was CNY 383,793,068.50, a decrease from CNY 441,084,902.73 in the previous period[52] - Net profit for Q1 2021 was CNY 56,853,356.28, compared to CNY 19,757,684.92 in the same period last year, representing a significant increase[54] Cash Flow and Assets - The net cash flow from operating activities improved to ¥82,294,323.13, a turnaround from a negative cash flow of ¥141,872,633.41 in the same period last year, marking a 158.05% increase[8] - The company's cash and cash equivalents increased to CNY 1,036,105,939.24 from CNY 882,820,386.78, representing a growth of about 17.38%[43] - The company's inventory as of March 31, 2021, was CNY 785,359,798.51, up from CNY 756,059,316.99, marking an increase of about 3.93%[43] - The cash flow from operating activities showed improvement, contributing to the overall financial health[54] - The net cash flow from operating activities was ¥82,294,323.13, a recovery from a negative cash flow of -¥141,772,650.93 in the previous period[62] - The cash inflow from investment activities totaled ¥1,257,468,268.82, a significant increase from ¥498,780,992.82 in the previous period[62] - The ending balance of cash and cash equivalents was 437,045,885.06, a decrease from 566,349,879.44 at the beginning of the period[66] Shareholder Information - The total number of shareholders at the end of the reporting period was 35,713[13] - The largest shareholder, Shuai Fangwen, holds 41.38% of the shares, with a total of 853,574,906 shares[13] - The total equity attributable to the owners of the parent company was CNY 5,842,289,388.68, compared to CNY 5,766,463,090.69, showing a slight increase of approximately 1.31%[46] Investments and Projects - The company invested CNY 70 million in Cambodia for the construction of a sulfanilamide project, enhancing its advantages in the pharmaceutical raw material sector[31] - A total of CNY 180.4025 million was allocated for a project in Cambodia to produce 10,000 tons of aniline, aimed at enriching the product line and reducing production costs[31] - The company established a wholly-owned subsidiary in the Yueyang area of the Hunan Free Trade Zone with an investment of CNY 5 million, focusing on the sale of pre-packaged and bulk food products[33] - The company has established a new holding subsidiary, Sukang Bio, with an investment of USD 35 million in Lianyungang, Jiangsu Province[35] Risk Management and Compliance - The company is closely monitoring industry policy changes, particularly in the pharmaceutical sector, to adapt its product structure and maintain quality control[28] - The company is addressing risks related to raw material supply and price fluctuations by strengthening market monitoring and adjusting inventory management[29] - The company is implementing measures to mitigate the impact of the COVID-19 pandemic on its operations, including adjusting strategies and ensuring employee safety[29] - The company is committed to complying with environmental regulations and enhancing internal standards to manage waste produced during the manufacturing process[30] - The company has no reported violations regarding external guarantees during the reporting period[36] - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[37] Financial Position - Total assets at the end of the reporting period were ¥6,824,009,355.88, an increase of 4.23% from the end of the previous year[8] - The total current liabilities rose to CNY 890,447,995.59 from CNY 691,509,423.15, indicating an increase of approximately 28.73%[45] - Total liabilities rose to CNY 1,262,112,120.07 from CNY 1,005,024,207.19, indicating an increase in financial obligations[50] - The equity attributable to shareholders increased to CNY 4,258,078,041.51 from CNY 4,209,542,897.07[50] Other Financial Metrics - The company reported non-recurring gains of ¥10,560,734.46, primarily from government subsidies and asset disposals[10][11] - The company recorded a decrease in sales expenses to ¥8,271,607.51 from ¥9,228,326.73, reflecting improved cost management[57] - The financial income from interest increased to ¥5,602,012.76 compared to ¥1,203,408.45 in the previous period, indicating better financial management[57] - The company did not undergo an audit for the first quarter report[68] - The company did not apply the new leasing standards for the first quarter of 2021[67]